PMID: 16630454Apr 25, 2006Paper

Comparison of the effects of intravenous recombinant human brain natriuretic peptide and nitroglycerin in patients with decompensated acute heart failure: a multicenter, randomized, open-label, parallel-design study

Zhonghua xin xue guan bing za zhi
Recombinant Human Brain Natriuretic Peptide Study Group

Abstract

To compare the efficacy and safety of intravenous infusion recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin (NIT) in treating patients with decompensated acute heart failure. A total of 209 patients characterized of decompensated acute heart failure were enrolled in this multicenter, randomized, open-label, parallel-design study. The patients were randomly allocated to catheter group and non-catheter group (depending on the use of Swan-Ganz). Each group was then randomly assigned to receive rhBNP (0.15 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(-1).min(-1) for 24 hours, n = 105) or NIT (starting at 10 microg/min and increasing 5 microg/min each time till clinical effective dose for 24 hours, n = 104). Blood pressure, heart rate, dyspnea grade, 24 hours fluid in- and output and improvement in patient symptoms and signs were evaluated and adverse events were documented. Urine output was significantly increased after both rhBNP and NIT treatments. Dyspnea and symptom improvements were more significant in rhBNP group compared to NIT group. PCWP and PAP were both decreased after rhBNP and NIT therapies and there was more significant reduction in PCWP and PAP between 30 min and 2 hours ...Continue Reading

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.